Development of Organoids From Primary Colorectal Tumors and Synchronous Liver Metastases

NCT ID: NCT06787625

Last Updated: 2025-01-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-25

Study Completion Date

2028-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pilot feasibility study for the development of organoids from primary colorectal tumors and synchronous liver metastases, to prepare organoids from primary colorectal tumors and synchronous liver metastases. The organoids will allow us to study the function of genes targeted by the activity of the NF-Y/p53 complex.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Organoids will allow us to study the function of genes that are targets of the NF-Y/p53 complex activity. In these organoids, we will perform overexpression and/or silencing of these genes and assays of proliferation, invasion and motility. We will also perform functional assays in cocultures of the organoids with PBMCs from the same patients. This could allow the discovery of new pathways that could be targeted by targeted therapy and/or immunotherapy. Organoid preparation will be performed from fresh colorectal cancer tissue and liver metastasis following enzymatic digestion. Organoid culture medium and specific organic matrix will be used

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colo-rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients \> 18 years
* Histological and cytological diagnosis of colorectal cancer neoplasia that has developed a liver metastasis
* Patients who are candidates for surgery for colorectal cancer with liver metastasis
* Signing of the relevant informed consent form.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Regina Elena Cancer Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Giulia Piaggio, Biologist

Role: PRINCIPAL_INVESTIGATOR

IRCCS National Cancer Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

"Regina Elena" National Cancer Institute

Rome, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Giulia Piaggio, Biologist

Role: CONTACT

+39 0652662458

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Giulia Piaggio, Biologist

Role: primary

+39 0652662458

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RS87/IRE/24

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.